Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.9M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
22.4M
-
Shares change
-
+1.53M
-
Total reported value, excl. options
-
$391M
-
Value change
-
+$30.1M
-
Put/Call ratio
-
0.35
-
Number of buys
-
40
-
Number of sells
-
-63
-
Price
-
$17.46
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q1 2024
121 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q1 2024.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.4M shares
of 27.9M outstanding shares and own 80.44% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (2.1M shares), MORGAN STANLEY (2.05M shares), VANGUARD GROUP INC (1.93M shares), BlackRock Inc. (1.84M shares), ARMISTICE CAPITAL, LLC (1.24M shares), Krensavage Asset Management, LLC (1.12M shares), MARSHALL WACE, LLP (951K shares), NORTHERN TRUST CORP (933K shares), Caligan Partners LP (858K shares), and ACADIAN ASSET MANAGEMENT LLC (854K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.